JF
BCAX

Jump Financial’s Bicara Therapeutics BCAX Stock Holding History

Jump Financial’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Buy
+100,300
New +$2.24M 0.02% 725
2026
Q1 		– Sell
-20,988
Closed -$353K – 2510
2025
Q4 		$353K Buy
+20,988
New +$358K ﹤0.01% 1468

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jump Financial's BCAX Position: Q2 2026 in Review

Jump Financial opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 100,300 shares worth $2.98M. The stake represents 0.02% of the portfolio and ranks #725 among its holdings. This is a return to the name: Jump Financial previously reported a position in BCAX as recently as Q4 2025.

Jump Financial first reported a position in BCAX in Q4 2025 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Jump Financial held 100,300 shares of Bicara Therapeutics worth $2.98M as of Q2 2026.
  • Bicara Therapeutics was a new Jump Financial position in Q2 2026.
  • Bicara Therapeutics made up 0.02% of Jump Financial's portfolio in Q2 2026, its #725 holding.
  • Jump Financial first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.